The FDA has approved Lilly’s Verzenio, making it the third market entrant in a new class of drugs for breast cancer. Verzenio (abemaciclib) is now licensed to treat adult patients with hormone ...

Verzenio plus Faslodex improved PFS in HR+, HER2– advanced breast cancer post-CDK4/6i progression, reducing progression or death risk by 27%. Consistent treatment effects were observed across clinical ...